Takacs P, Kunovszki P, Timtschenko V, Feher L, Balazs T, Hegyi R
Schizophr Bull Open. 2024; 3(1):sgac013.
PMID: 39144770
PMC: 11205877.
DOI: 10.1093/schizbullopen/sgac013.
Hode Y, Padovani R, Hikmat W, Guillard-Bouhet N, Attal J, Bralet M
Front Psychiatry. 2024; 15:1370566.
PMID: 38638418
PMC: 11024790.
DOI: 10.3389/fpsyt.2024.1370566.
Chan C, Verma S, Subramaniam M, Abdin E, Tay J
Int J Environ Res Public Health. 2023; 20(4).
PMID: 36834095
PMC: 9961511.
DOI: 10.3390/ijerph20043403.
Brissos S, Taylor D
CNS Drugs. 2022; 36(4):315-325.
PMID: 35226350
DOI: 10.1007/s40263-022-00906-4.
Ibrahim H, Malcolm B, Gogineni H
Fed Pract. 2022; 38(12):586-591.
PMID: 35177888
PMC: 8843007.
DOI: 10.12788/fp.0195.
Wearables as a tool for measuring therapeutic adherence in behavioral health.
Wedlund L, Kvedar J
NPJ Digit Med. 2021; 4(1):79.
PMID: 33972676
PMC: 8110516.
DOI: 10.1038/s41746-021-00458-9.
Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics.
Mahlich J, Olbrich K, Wilk A, Wimmer A, Wolff-Menzler C
Clin Drug Investig. 2020; 41(1):99-113.
PMID: 33331979
PMC: 7815621.
DOI: 10.1007/s40261-020-00990-8.
[Suicidality in schizophrenic psychosis: a current overview].
Knorr R, Hoffmann K
Nervenarzt. 2020; 92(11):1186-1195.
PMID: 33165624
DOI: 10.1007/s00115-020-01028-2.
Prescription patterns of antipsychotics in the management of first episode psychosis at three psychiatric hospitals in Khartoum, 2018: A descriptive cross-sectional study.
Mohamed M, Yousef B
J Family Med Prim Care. 2020; 9(1):402-406.
PMID: 32110626
PMC: 7014859.
DOI: 10.4103/jfmpc.jfmpc_892_19.
Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications.
Stroup T, Bareis N, Rosenheck R, Swartz M, McEvoy J
J Clin Psychiatry. 2018; 80(1).
PMID: 30549494
PMC: 6296243.
DOI: 10.4088/JCP.18m12109.
Regularity of self-reported daily dosage of mood stabilizers and antipsychotics in patients with bipolar disorder.
Pilhatsch M, Glenn T, Rasgon N, Alda M, Sagduyu K, Grof P
Int J Bipolar Disord. 2018; 6(1):10.
PMID: 29713845
PMC: 6161976.
DOI: 10.1186/s40345-018-0118-8.
Can a digital medicine system improve adherence to antipsychotic treatment?.
Papola D, Gastaldon C, Ostuzzi G
Epidemiol Psychiatr Sci. 2018; 27(3):227-229.
PMID: 29528032
PMC: 6998860.
DOI: 10.1017/S2045796018000082.
Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole.
Remmerie B, De Meulder M, Ariyawansa J, Savitz A
Clin Pharmacol Drug Dev. 2016; 5(6):538-547.
PMID: 27363344
PMC: 5132144.
DOI: 10.1002/cpdd.291.
Nurses' perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire survey.
Emsley R, Alptekin K, Azorin J, Canas F, Dubois V, Gorwood P
Ther Adv Psychopharmacol. 2016; 5(6):339-50.
PMID: 26834967
PMC: 4722504.
DOI: 10.1177/2045125315612013.
Adherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data.
Kuwabara H, Saito Y, Mahlich J
Neuropsychiatr Dis Treat. 2015; 11:935-40.
PMID: 25897229
PMC: 4389915.
DOI: 10.2147/NDT.S81677.
Development and application of an aggregate adherence metric derived from population pharmacokinetics to inform clinical trial enrichment.
Knights J, Rohatagi S
J Pharmacokinet Pharmacodyn. 2015; 42(3):263-73.
PMID: 25821065
PMC: 4432109.
DOI: 10.1007/s10928-015-9414-4.
Money for medication: a randomized controlled study on the effectiveness of financial incentives to improve medication adherence in patients with psychotic disorders.
Noordraven E, Audier C, Staring A, Wierdsma A, Blanken P, van der Hoorn B
BMC Psychiatry. 2014; 14:343.
PMID: 25438877
PMC: 4258939.
DOI: 10.1186/s12888-014-0343-3.
Partial compliance with antipsychotics increases mental health hospitalizations in schizophrenic patients: analysis of a national managed care database.
Kozma C, Weiden P
Am Health Drug Benefits. 2014; 2(1):31-8.
PMID: 25126270
PMC: 4106590.
What's in a name? Compliance, adherence and concordance in chronic psychiatric disorders.
Chakrabarti S
World J Psychiatry. 2014; 4(2):30-6.
PMID: 25019054
PMC: 4087153.
DOI: 10.5498/wjp.v4.i2.30.
Development of Risperidone PLGA Microspheres.
DSouza S, Faraj J, Giovagnoli S, DeLuca P
J Drug Deliv. 2014; 2014:620464.
PMID: 24616812
PMC: 3927762.
DOI: 10.1155/2014/620464.